HPPH
Based on 3 publication(s) in Google Scholar
HPPH (Photochlor) is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.74%
- CAS No.: 149402-51-7
- Formule: C39H48N4O4
- Masse moléculaire:636.82
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Rare Diseases Drug Library
HY-L102
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) HPPH
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.33 μM
Compound: HPPH
|
Phototoxicity against human A549 cells assessed as reduction in cell proliferation irradiated with 1 J/cm2 of 650 nanometer laser light preincubated for 24 hrs measured after 48 hrs by MTT assay
Phototoxicity against human A549 cells assessed as reduction in cell proliferation irradiated with 1 J/cm2 of 650 nanometer laser light preincubated for 24 hrs measured after 48 hrs by MTT assay
|
[PMID: 31846830] |
| FaDu | IC50 |
43.8 nM
Compound: HPPH
|
Photosensitizing activity in human FaDu cells assessed as reduction in cell viability pretreated with compound for 24 hrs followed by light irradiation at 1 J/cm2 and measured after 48 hrs by MTT assay
Photosensitizing activity in human FaDu cells assessed as reduction in cell viability pretreated with compound for 24 hrs followed by light irradiation at 1 J/cm2 and measured after 48 hrs by MTT assay
|
[PMID: 33400524] |
| UMUC3 | IC50 |
68.4 nM
Compound: HPPH
|
Photosensitizing activity in human UMUC3 cells assessed as reduction in cell viability pretreated with compound for 24 hrs followed by light irradiation at 1 J/cm2 and measured after 48 hrs by MTT assay
Photosensitizing activity in human UMUC3 cells assessed as reduction in cell viability pretreated with compound for 24 hrs followed by light irradiation at 1 J/cm2 and measured after 48 hrs by MTT assay
|
[PMID: 33400524] |
Fluorescence image of 4T1 cells incubated with 0.49 µg/mL GO-PEG, 1 μM HPPH (free HPPH) or equivalent amount of GO-PEG-HPPH (1 µM HPPH and 0.49 µg/mL GO-PEG) after 24 h. The cellular uptake of GO-PEG-HPPH and HPPH is investigated with 4T1 murine mammary cancer cells. The cells are incubated with GO-PEG-HPPH and free HPPH at equivalent HPPH concentration (1 µM) for 24 h and then observed with a confocal microscope. Cells treated with GO-PEG-HHPH shows stronger fluorescence signal than those treated with free HPPH. In fact, the fluorescence of HPPH is rather weak[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 149402-51-7
-
Appearance Solid
-
Masse moléculaire 636.82
-
Formule C39H48N4O4
-
Color Light brown to black
-
SMILES
OC(CC[C@H](/C1=C(C2=C3C(C)=C(N2)/C=C4C(CC)=C(C(/C=C5N/C(C(C)=C\5C(OCCCCCC)C)=C\C6=N1)=N/4)C)\CC3=O)[C@@H]6C)=O
-
Synonyms
Photochlor
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer. [Abstract]2021 May 19;19(1):147. PMID: 34011362 -
Research (Wash D C)
Traceable Lactate-Fueled Self-Acting Photodynamic Therapy against Triple-Negative Breast Cancer. [Abstract]2024 Jan 17:7:0277. PMID: 40771576 -
ACS Appl Mater Interfaces
Instant Ultrasound-Evoked Precise Nanobubble Explosion and Deep Photodynamic Therapy for Tumors Guided by Molecular Imaging. [Abstract]2021 May 12;13(18):21097-21107. PMID: 33908256
Solvant et solubilité
DMSO : 2 mg/mL (3.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.93 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
4T1 cells are cultured in 96-well cell culture plates at 1×104/well for 24 h and then treated with GO-PEG-HPPH, HPPH, or GO-PEG at a series of concentrations (0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 μM). Then, 20 µL of MTT solution (5.0 mg/mL) is added to each well. After the 4 h incubation with the MTT, the media are removed and 100 µL of DMSO is added to solubilize the formazan crystals. The cell toxicity efficacy is measured with a microplate reader at an absorbance of 570 nm[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Tumor-bearing mice are injected in the tail vein with 0.4 μmol/kg HPPH or 5 mg/kg Porfimer sodium (PII), followed 18-24 h later by illumination to a total light dose of 48 J/cm2 or 132 J/cm2 delivered at a light dose-rate of 14 mW/cm2. Control mice are treated with photosensitizer or light alone. Mice receiving a combination PDT regimen are treated initially with 0.4 μmol/kg HPPH or 5 mg/kg PII followed 18-24 h later by light dose of 48 J/cm2 given at 14 mW/cm2; 9 days later, mice are again injected with photosensitizer and tumors are illuminated with light at a dose of 132 J/cm2 given at 14 mW/cm2[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Rong P, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014 Jan 15;4(3):229-39. [Content Brief]
[2]. Shams M, et al. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol Immunother. 2015 Mar;64(3):287-97. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5703 mL | 7.8515 mL | 15.7030 mL | 39.2576 mL |
HPPH Related Classifications
HY-13722 Related Classifications
Powered by Bioz